Influenza Vaccines
Inactivated, live-attenuated, recombinant, and adjuvanted vaccines
This page catalogs 20 influenza vaccine products spanning seasonal, pandemic, and stockpile formulations. Influenza vaccines represent the broadest range of manufacturing platforms for any single disease — including egg-based, cell-based, recombinant, adjuvanted, live-attenuated intranasal, and pandemic-specific products.
Last updated: April 2026.
Influenza Vaccine Catalog
| Trade Name | Generic Designation | Manufacturer | Vaccine Type | Regulatory Status & Year | Key Notes |
|---|---|---|---|---|---|
| Fluzone / Fluzone HD | Influenza virus vaccine (inactivated) | Sanofi Pasteur | Inactivated (egg-based) | FDA Licensed | Standard and high-dose formulations |
| FluMist | Influenza vaccine, live intranasal | MedImmune/AstraZeneca | Live-attenuated (intranasal) | FDA Licensed, 2003 | Nasal spray; trivalent and quadrivalent |
| Fluad / Fluad Quadrivalent | Influenza vaccine, adjuvanted | Seqirus (CSL) | Inactivated + MF59 adjuvant | FDA Licensed, 2015 | MF59-adjuvanted for ages 65 and older |
| Flucelvax Quadrivalent | Influenza vaccine (cell culture) | Seqirus (CSL) | Inactivated (cell-based) | FDA Licensed, 2012 | Cell-culture based; egg-free |
| Flublok / Flublok Quadrivalent | Influenza vaccine (recombinant) | Sanofi Pasteur | Recombinant HA protein | FDA Licensed, 2013 | Recombinant; egg-free; ages 18+ |
| Afluria / Afluria Quadrivalent | Influenza vaccine | Seqirus (CSL) | Inactivated (egg-based) | FDA Licensed | Standard quadrivalent formulation |
| Fluvirin / Fluvirin Quadrivalent | Influenza vaccine | Seqirus (CSL) | Inactivated (egg-based) | FDA Licensed | Ages 4+ formulation |
| Fluarix / Fluarix Quadrivalent | Influenza vaccine | GSK | Inactivated (egg-based) | FDA Licensed | Ages 6 months+ formulation |
| FluLaval / FluLaval Quadrivalent | Influenza vaccine | GSK | Inactivated (egg-based) | FDA Licensed | Ages 6 months+ formulation |
| Agriflu | Influenza vaccine | Seqirus (CSL) | Inactivated (egg-based) | FDA Licensed | Ages 18+ formulation |
| Fluzone Intradermal | Influenza vaccine (intradermal) | Sanofi Pasteur | Inactivated (egg-based, intradermal) | FDA Licensed; Discontinued | Intradermal delivery; discontinued |
| Audenz | A/H5N1 influenza vaccine, adjuvanted | Seqirus (CSL) | Inactivated + MF59 adjuvant (pandemic) | FDA Licensed, 2015 | Pandemic H5N1 stockpile vaccine |
| Fluad Pediatric | Influenza vaccine, adjuvanted (pediatric) | Seqirus (CSL) | Inactivated + MF59 adjuvant | FDA Licensed, 2022 | Pediatric MF59-adjuvanted formulation |
| Influvac | Influenza vaccine | Viatris (Mylan) | Inactivated (egg-based) | EMA Authorized | European formulation |
| Vaxigrip / VaxigripTetra | Influenza vaccine | Sanofi Pasteur | Inactivated (egg-based) | EMA Authorized | European and international formulation |
| Alfana | Influenza vaccine (cell-based) | Seqirus (CSL) | Inactivated (cell-based) | EMA Authorized | European cell-culture formulation |
| OptaFlu | Influenza vaccine (cell-based) | Novartis/Sequirus | Inactivated (cell-based) | EMA Authorized; Discontinued | European cell-based; discontinued |
| Supemtek | Influenza vaccine (recombinant) | Sanofi Pasteur | Recombinant HA protein | FDA Licensed, 2020 | Recombinant; egg-free; ages 18+ |
| Arexvy (RSV+Influenza) | RSV + Influenza combination | GSK | Combination (adjuvanted) | FDA Licensed, 2025 | First approved RSV-flu combination |
Sources
Regulatory data sourced from FDA CBER Vaccines Licensed for Use in the United States (March 2026) and EMA Medicines database. Catalog scope informed by Khan, Shaz, The Ultimate Vaccine Timeline.